atl1102 update, page-9

Thing I still don't get is all that has been known about ATL-1102 including the Phase II data has been known by the industry for A LONG TIME, Teva walked 3 and a half years ago whilst ATL-1102 sat idle. The chronic toxicology study was really not a big ask for a partner or potential one to undertake if they had a lot of interest in the already known data - but they didn't until eventually TJAB came along to stick there nose & ANP ended up funding it anyway. So while I think it's all well and good to say if the CTS results are favourable "it will be undertaken with a pharmaceutical development partner" the crux of that remains to be seen if they're not already lined up.

Interesting 2014 on many fronts anyway.